Medication Research in Pregnancy
Cross-source consensus on Medication Research in Pregnancy from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Highlighted claims
- MR-PREG aims to use genomics to evaluate medication safety and efficacy during pregnancy. — Cohort profile: the Mendelian randomisation in pregnancy (MR-PREG) collaboration – improving evidence for prevention and treatment of adverse pregnancy and perinatal outcomes
- MR-PREG uses drug target MR to investigate drugs for pre-existing conditions, identify new candidate drug targets, and find repurposing opportunities. — Cohort profile: the Mendelian randomisation in pregnancy (MR-PREG) collaboration – improving evidence for prevention and treatment of adverse pregnancy and perinatal outcomes
- Future work includes discovering candidate drug targets and assessing safety, efficacy, and repurposing potential of existing drugs during pregnancy. — Cohort profile: the Mendelian randomisation in pregnancy (MR-PREG) collaboration – improving evidence for prevention and treatment of adverse pregnancy and perinatal outcomes
- One MR study of 1,139 maternal and fetal circulating proteins implicated glucose metabolism, energy balance, and vascular function in offspring birth weight. — Cohort profile: the Mendelian randomisation in pregnancy (MR-PREG) collaboration – improving evidence for prevention and treatment of adverse pregnancy and perinatal outcomes
- MR-PREG found signals that PCSK1 and LGALS4 may influence birth weight differently depending on whether maternal or fetal genetically predicted protein levels are considered. — Cohort profile: the Mendelian randomisation in pregnancy (MR-PREG) collaboration – improving evidence for prevention and treatment of adverse pregnancy and perinatal outcomes